11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months
6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less at 6 months
Zetomipzomib continues to demonstrate a favorable safety and tolerability profile for administration over the 6-month treatment period
Improvement seen in exploratory measures of extra-renal disease activity associated with systemic lupus erythematosus (SLE) in patients who completed treatment
Company-hosted conference call and webcast to be held today at 4:30 p.m. ET
Kezar Life Sciences will host a webcast and conference call today, June 27, 2022, at 4:30 p.m. ET to discuss topline data from the MISSION Phase 2 clinical trial. To access the audio webcast with slides, please visit the "Events & Presentations" page in the Investors & Media section of the Company’s website at https://ir.kezarlifesciences.com/news-events/events-presentations. The call can also be accessed by dialing +1 (800) 309-0220 (domestic) or +1 (805) 309-0220 (international) with conference ID 6423042#.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.